No statistically significant differences were detected in neutrophil, gender, never smoker, hypertension, ALK rearrangement, EGFR mutation, tumor stage, ECOG PS score, number of metastases, number of previous treatment lines, previous targeted therapy, previous radiotherapy, previous immunotherapy and anlotinib monotherapy (all p values > 0.05). This evidence concerns the gene ALK and neoplasm.